19-JUL-2024 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

55% of Calendar Year is Past

COMMITTEE Base Accrual
2010
2024
Accrual
to date
Percentage
of Base
Accrual
Projected
2024
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1564 261 17% 473 -1090 326 -1238
ERLYTX 76 24 32% 43 -32 43 -33
GI 479 124 26% 225 -253 214 -265
GU 450 305 68% 553 103 531 81
GYN 57 0 0% 0 -57 0 -57
LEUK 150 31 21% 56 -93 50 -100
LUNG 524 483 92% 877 353 826 302
LYMPH 172 119 69% 216 44 194 22
MELAN 55 254 462% 461 406 461 406
MMYEL 147 165 112% 299 152 195 48
MULT 0 22   39 39 22 22
OTHER 0 41   74 74 63 63
PREV 0 2   3 3 4 4
SXQOL 0 5   9 9 6 6
Total 3674 1836   3328 -342 2935 -739

19-JUL-2024 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

55% of Calendar Year is Past

COMMITTEE Base Accrual
2010
2024
Accrual
to date
Percentage
of Base
Accrual
Projected
2024
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 1   1 1 1 1
BREAST 43 0 0% 0 -43 0 -43
CCD 0 480   871 871 910 910
ERLYTX 0 7   12 12 10 10
GI 0 3   5 5 3 3
GU 0 6   10 10 8 8
LEUK 69 5 7% 9 -59 5 -64
LUNG 43 188 437% 341 298 341 298
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 7   12 12 9 9
PEOLC 0 1   1 1 12 12
PREV 0 292   530 530 543 543
SURV 0 7   12 12 10 10
SXQOL 888 750 84% 1361 473 1366 478
Total 1188 1747   3165 1978 3218 2030

19-JUL-2024 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

55% of Calendar Year is Past

COMMITTEE Base Accrual
2010
2024
Accrual
to date
Percentage
of Base
Accrual
Projected
2024
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 1   1 1 1 1
BREAST 1607 261 16% 473 -1133 326 -1281
CCD 0 480   871 871 910 910
ERLYTX 76 31 41% 56 -19 53 -23
GI 479 127 27% 230 -248 217 -262
GU 450 311 69% 564 114 539 89
GYN 57 0 0% 0 -57 0 -57
LEUK 219 36 16% 65 -153 55 -164
LUNG 567 671 118% 1218 651 1167 600
LYMPH 225 119 53% 216 -8 194 -31
MELAN 55 254 462% 461 406 461 406
MMYEL 239 165 69% 299 60 195 -44
MULT 0 22   39 39 22 22
OTHER 0 48   87 87 72 72
PEOLC 0 1   1 1 12 12
PREV 0 294   533 533 547 547
SURV 0 7   12 12 10 10
SXQOL 888 755 85% 1371 483 1372 484
Total 4862 3583   6497 1640 6153 1291

19-JUL-2024 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

55% of Calendar Year is Past

COMMITTEE Base Accrual
2010
2024
Accrual
to date
Percentage
of Base
Accrual
Projected
2024
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1018 147 14% 266 -751 199 -819
ERLYTX 76 19 25% 34 -41 34 -42
GI 421 107 25% 194 -226 180 -241
GU 375 256 68% 464 89 431 56
GYN 57 0 0% 0 -57 0 -57
LEUK 122 19 16% 34 -87 30 -92
LUNG 441 308 70% 559 118 551 110
LYMPH 129 96 74% 174 45 157 28
MELAN 55 146 265% 265 210 274 219
MMYEL 85 105 124% 190 105 128 43
MULT 0 12   21 21 12 12
OTHER 0 40   72 72 62 62
PREV 0 2   3 3 4 4
SXQOL 0 5   9 9 6 6
Total 2779 1262   2285 -490 2068 -711

19-JUL-2024 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

55% of Calendar Year is Past

COMMITTEE Base Accrual
2010
2024
Accrual
to date
Percentage
of Base
Accrual
Projected
2024
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 16 0 0% 0 -16 0 -16
CCD 0 422   766 766 801 801
ERLYTX 0 7   12 12 10 10
GI 0 3   5 5 3 3
GU 0 6   10 10 8 8
LEUK 69 0 0% 0 -69 0 -69
LUNG 30 111 370% 201 171 197 167
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 7   12 12 9 9
PEOLC 0 1   1 1 6 6
PREV 0 211   383 383 374 374
SURV 0 7   12 12 10 10
SXQOL 750 478 64% 868 118 880 130
Total 1010 1253   2270 1260 2298 1288

19-JUL-2024 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

55% of Calendar Year is Past

COMMITTEE Base Accrual
2010
2024
Accrual
to date
Percentage
of Base
Accrual
Projected
2024
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1034 147 14% 266 -767 199 -835
CCD 0 422   766 766 801 801
ERLYTX 76 26 34% 47 -28 44 -32
GI 421 110 26% 199 -221 183 -238
GU 375 262 70% 475 100 439 64
GYN 57 0 0% 0 -57 0 -57
LEUK 191 19 10% 34 -156 30 -161
LUNG 471 419 89% 760 289 748 277
LYMPH 182 96 53% 174 -7 157 -25
MELAN 55 146 265% 265 210 274 219
MMYEL 177 105 59% 190 13 128 -49
MULT 0 12   21 21 12 12
OTHER 0 47   85 85 71 71
PEOLC 0 1   1 1 6 6
PREV 0 213   386 386 378 378
SURV 0 7   12 12 10 10
SXQOL 750 483 64% 877 127 886 136
Total 3789 2515   4558 774 4366 577

19-JUL-2024 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

55% of Calendar Year is Past

COMMITTEE Base Accrual
2010
2024
Accrual
to date
Percentage
of Base
Accrual
Projected
2024
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 65 258 397% 468 403 315 250
CCD 0 480   871 871 910 910
ERLYTX 0 0   0 0 1 1
GI 81 9 11% 16 -64 21 -60
GU 215 249 116% 452 237 446 231
LEUK 0 24   43 43 35 35
LUNG 53 156 294% 283 230 259 206
LYMPH 7 58 829% 105 98 97 90
MELAN 0 0   0 0 0 0
MMYEL 0 161   292 292 191 191
OTHER 0 11   19 19 19 19
PEOLC 0 1   1 1 12 12
PREV 0 218   395 395 397 397
SURV 0 7   12 12 10 10
SXQOL 880 755 86% 1371 491 1372 492
Total 1301 2387   4328 3028 4085 2784

19-JUL-2024 6:11

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm. Phase Study Stat
Center
Open
Date
Months
Open
Total
Regs
Accrual
Goal
Monthly
Accrual
Rate
Date of
Expected Closure or
Temporary Closure
    A022101 ALLIANCE     0      
    EAY191A6 ALLIANCE     1      
BREAST II EA1211 Breast, HER2+, NeoAdj Therapy ECOG-ACRIN 10MAY2023:00:00:00   2   0.3  
    NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG 13APR2017:00:00:00   7     Dec-2022 Temp Close
    S2007 Breast, Brain Mets, Sacituzumab Govitecan SWOG 15DEC2020:00:00:00 43 24 44 0.2 Jun-2034
  II-III NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG 24DEC2014:00:00:00   1     May-2022 Temp Close
  III A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib ALLIANCE 06JAN2021:00:00:00   44   0.7  
    A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab ALLIANCE 03MAY2023:00:00:00   8   0.7  
    MA39 BREAST, Node-Pos, Reg RT vs No Reg RT CCTG 30MAY2018:00:00:00   31   1.5  
    NRGBR007 Breast, Stg I, De-Escalation of Breast RT NRG 07JUN2021:00:00:00   9   0.2  
    NRGBR009 Breast, EarlyStg, Adjuvant Chemo NRG 31AUG2023:00:00:00   4   0.7  
    S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva SWOG 30OCT2023:00:00:00 8 30 960 5.0 > 15 Yrs
    S2212 Breast, TNBC, Neoadj Chemo + Pembro SWOG 21JUL2023:00:00:00 11 213 2400 29.0 Oct-2030
CCD III A191901 Brst, Text/Motivational Intervention ET Adher ALLIANCE 10DEC2020:00:00:00   40   0.2  
    S1703 Met Breast, STM-monitoring v Usual Care SWOG 16JUL2018:00:00:00 72 346 739 5.5 Jun-2030
    S1912CD CREDIT, Fin Counseling to reduce Fin Hardship SWOG 26JUL2021:00:00:00 35 267 326 15.5 Oct-2024
    S2108CD Genomic Tumor Board vs Usual Practice SWOG 22AUG2022:00:00:00 22 1098 1182 49.0 Aug-2024
  OTHER A231602C Blood Cancer, Assess Financial Difficulty ALLIANCE 15MAR2019:00:00:00   4     Feb-2021 Temp Close
    A231901C Breast, Shared Decision Engagement System ALLIANCE 15JAN2021:00:00:00   2   0.0  
    ACCL16N1 Guideline Consistent Treatment AYA ALL COG 18DEC2017:00:00:00   54     Aug-2022 Temp Close
ERLYTX II A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib ALLIANCE 28AUG2015:00:00:00   8   0.0  
    EAY191-S3 ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib SWOG 06MAR2023:00:00:00 16 3 33 0.3 Dec-2031
    EAY191A3 ComboMATCH-RAS-Mutant, All Stg, Palbo+Benim ALLIANCE 15NOV2023:00:00:00   2   0.3  
    EAY191E4 ComboMATCH-Pr. Tax-Tx Tumors, Pac+Nilotinib ECOG-ACRIN 07JUN2023:00:00:00   3   0.0  
  II-III S2012 Small Cell NEC, Stg IV, Combo Chemo +/- Atezo SWOG 02DEC2021:00:00:00 31 52 189 3.0 Apr-2028
  III AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult COG 08MAY2017:00:00:00   2   0.0  
  OTHER EAY191 ComboMATCH ECOG-ACRIN 06MAR2023:00:00:00   10   1.2  
GI II A022001 PANC, METS, Lu 177 Dotatate PRRT vs CAPTEM ALLIANCE 16MAR2022:00:00:00   2   0.0  
    A022104 Rectal, Loc Adv, Triplet vs Doublet Chemo ALLIANCE 09NOV2022:00:00:00   62   4.7  
    CCTGNE1 Midgut NET, Unresect, 177 Lut vs Ever CCTG 05JUN2023:00:00:00   1   0.2  
    EA2182 Anal, Erly, DECREASE ECOG-ACRIN 12NOV2019:00:00:00   14   0.2  
    EA2192 Panc, APOLLO ECOG-ACRIN 29APR2021:00:00:00   2   0.0  
    S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect SWOG 16DEC2019:00:00:00 55 34 94 0.7 Dec-2031
    S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo SWOG 04DEC2020:00:00:00 43 54 88 1.3 Aug-2026
    S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs SWOG 14OCT2021:11:13:50 33 47 154 2.2 Aug-2028
    S2107 Colorectal, BRAF mut, Enc + CET +/-Nivo SWOG 06JUN2022:10:01:28 25 74 84 4.2 Sep-2024
  II-III A022004 Colon, Stg II-III, Encor+Cetux vs SOC ALLIANCE 30MAY2023:00:00:00   0   0.0  
    EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab ECOG-ACRIN 17JAN2019:00:00:00   6   0.0  
    EA2197 Gal, Rando Perioperative TX ECOG-ACRIN 22DEC2020:00:00:00   7   0.3  
    NRGGI008 Colon, Stg III, Adj Chemo NRG 10MAR2022:00:00:00   21   1.2  
    S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo SWOG 06MAY2024:00:00:00 2 1 224    
  III A021806 Pancreas, Perioperative vs Adjuvant Chemo ALLIANCE 01JUL2020:00:00:00   30   0.3  
    A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo ALLIANCE 11JAN2023:00:00:00   17   2.0  
    CCTGCO32 Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad CCTG 29FEB2024:00:00:00   1   0.2  
    EA2176 Anal, Met, Immune Check Pt Inhibition + Chemo ECOG-ACRIN 15OCT2020:00:00:00   32   1.3  
    EA2222 Colorectal, Stg II-III, Hep Art Infusion ECOG-ACRIN 19OCT2023:00:00:00   1   0.2  
    NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG 07NOV2017:00:00:00 80 15   0.0  
    NRGGI006 Esophagus, Stg I-IVA, PBT vs IMRT NRG 06MAR2019:00:00:00   1   0.2  
GU II A021804 Adren, Advanced Stg, Temo w/wo Ola ALLIANCE 02NOV2020:00:00:00   1   0.2  
    A031701 Bladder, ddGC for MIBC with DDR Tumor Alt ALLIANCE 01AUG2018:00:00:00   23   0.7  
    A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) ALLIANCE 12APR2019:00:00:00   26   0.0  
    A031801 GU, mRCC, Cabozantinib +/- Radium-223 ALLIANCE 13DEC2019:00:00:00   15   0.3  
    A031803 Blad, NMIBC, Gemcitabine + MK-3475 ALLIANCE 06JAN2020:00:00:00   44   0.7  
    EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi ECOG-ACRIN 09JUL2018:00:00:00   90   0.5  
    NRGGU011 Pros, Dbl Blinded RT +/- Androgen Dep Tx NRG 08DEC2021:00:00:00   9   0.2  
    NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy NRG 30JUN2022:00:00:00   3   0.3  
    S2200 pRCC, Adv, Cabo +/- Atezo SWOG 19SEP2022:00:00:00 22 23 200 2.3 Oct-2030
    S2210 Pros, High Risk, BRCA, Neoadj Carbo SWOG 14AUG2023:00:00:00 11 1 44 0.2 > 15 Yrs
  II-III A032103 Urothelial, All Stg, MRD-Based Adj Tx ALLIANCE 09JAN2024:00:00:00   2   0.3  
    EA8192 Blad, High Grade UTUC, Durv + Chemo ECOG-ACRIN 06MAY2021:00:00:00   3   0.2  
  III EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT ECOG-ACRIN 08SEP2017:00:00:00   13   0.2  
    EA8191 Pros, Local vs Systemic Thrpy ECOG-ACRIN 08OCT2020:00:00:00   43   2.7  
    EA8212 Blad, NMIBC, BRIDGE ECOG-ACRIN 01DEC2022:00:00:00   130   10.2  
    NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide NRG 05MAR2020:00:00:00   14   0.7  
    NRGGU009 Pros, PREDICT-RT NRG 15DEC2020:00:00:00   63   4.5  
    NRGGU010 Pros, Parallel De-Intens & Intens Trials NRG 03NOV2021:00:00:00   36   1.3  
    NRGGU013 Prostate, High-Risk, Five Fraction Radiation NRG 13NOV2023:00:00:00   2   0.3  
    S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum SWOG 17SEP2018:00:00:00 70 823 1273 10.8 Dec-2027
    S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only SWOG 16NOV2020:00:00:00 44 98 332 2.0 Mar-2034
    S1937 Blad, Mets, Eribulin + Gem vs SOC SWOG 16FEB2021:00:00:00 41 39 184 2.7 Jan-2029
LEUK I-II EA9152 ALL, T/B-Cell, Venetoclax + Vincristine ECOG-ACRIN 26APR2018:00:00:00   3   0.2  
    S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 SWOG 17AUG2020:00:00:00 47 15 64 0.2 > 15 Yrs
  II A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat ALLIANCE 16NOV2018:00:00:00   5   0.0  
    A042001 B-Cell ALL, Inotuzunab+chemo v Standard chemo ALLIANCE 27FEB2023:00:00:00   2   0.0  
    EA9171 CML, Anti-PD-1 Pembrolizumab + TKIs ECOG-ACRIN 03OCT2018:00:00:00   4   0.2  
    EA9213 T-ALL, dara-hyal for chemo refractory MRD ECOG-ACRIN 16JUN2022:00:00:00   3   0.0  
    MM1YA-S01 AML, High Risk, Age <60, 7+3 vs experimental SWOG 16MAY2024:00:00:00 2 0 335    
  II-III A041701 AML, Age 60+, Conv Chemo +/- Uproleselan ALLIANCE 16JAN2019:00:00:00   38   0.0  
  III A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo ALLIANCE 01JUN2017:00:00:00   44   0.0  
    EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab ECOG-ACRIN 14OCT2020:00:00:00   34   0.7  
    S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O SWOG 14DEC2020:00:00:00 43 109 247 3.5 Oct-2027
  OTHER MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials SWOG 16MAY2024:00:00:00 2 5      
LUNG II EA5162 NSCLS,StgIV/IIB,EGFR exon20 insertion,AZD9291 ECOG-ACRIN 05APR2018:00:00:00   1   0.0  
    S1900E KRAS G12C: Sotorasib (AMG 510) SWOG 02APR2021:00:00:00 39 115 116 1.0 Jul-2024
    S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu SWOG 03APR2023:00:00:00 15 13 66 0.8 Oct-2029
    S1900K MET Exon 14: Tepotinib +/- Ramucirumab SWOG 18DEC2023:00:00:00 7 0 56 0.0 > 15 Yrs
    S1933 NSCLC, Stg II-III, RT + Atezo SWOG 15JUN2020:10:15:53 49 39 47 1.0 Feb-2025
  II-III A082002 Lung, Adv, Systemic Tx +/- SBRT ALLIANCE 21DEC2021:00:00:00   4   0.0  
  III A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO ALLIANCE 03JUN2020:00:00:00   79   1.7  
    EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 ECOG-ACRIN 22OCT2020:00:00:00   17   1.0  
    NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo NRG 10MAY2023:00:00:00   1   0.2  
    S1827 SCLC, MRI Surveillance +/- PCI SWOG 10JAN2020:00:00:00 54 230 668 7.0 Sep-2029
    S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo SWOG 25MAR2020:00:00:00 51 397 480 15.2 Dec-2024
    S2302 NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC SWOG 06MAR2023:08:56:25 16 554 700 43.5 Oct-2024
  OTHER A151216 ALCHEMIST0 - screening ALLIANCE 18AUG2014:00:00:00   976   1.3  
    LUNGMAP NSCLC, Adv, Master SWOG 28JAN2019:00:00:00 65 3427   26.8  
LYMPH I-II E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin ECOG-ACRIN 24JAN2014:00:00:00   20   0.0  
  II A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P ALLIANCE 30JUL2021:00:00:00   7   1.0  
    S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation SWOG 23FEB2023:11:55:36 16 63 396 5.7 May-2029
    S2207 LBCL, Transplant Inelig, Targeted Tx + Tafa SWOG 30JUN2023:11:49:39 12 20 227 2.5 May-2031
  II-III S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP SWOG 19MAR2021:00:00:00 40 110 422 4.0 Dec-2030
  III A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub ALLIANCE 08SEP2023:00:00:00   7   1.0  
    AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy COG 28APR2023:00:00:00   19   1.2  
    ANHL1931 PMBCL, Chemo-Immunotherapy +/- Nivo COG 07JUN2021:00:00:00   22   1.2  
    EA4151 Lymph, AHCT +/-Ritux, MRD Neg ECOG-ACRIN 29AUG2017:00:00:00   132   2.0  
MELAN II A091903 Melan, Resected Mucosal, Adj Nivo +/- Cabo ALLIANCE 01JUN2022:00:00:00   1   0.0  
    EA6192 Melan, Adv, Erly Discont of Antibdy Thrpy ECOG-ACRIN 27AUG2020:00:00:00   9   0.2  
    EA6194 Melan, Stage IIIB-D, Pembro +/- CMP-001 ECOG-ACRIN 19MAR2021:00:00:00   4   0.5  
  II-III EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 10SEP2015:00:00:00   62   0.5  
  III S2015 MELAN, Stg I-II, 1cm v 2cm excision margins MASC 08APR2022:00:00:00   706   37.2  
MMYEL II EAA173 MYEL, SMM, Rd +/- Daratumumab ECOG-ACRIN 30APR2019:00:00:00   32   1.0  
  III EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) ECOG-ACRIN 27OCT2020:00:00:00   35   0.5  
    S1803 MM, Maintenance, Len vs Len/Dara SWOG 27JUN2019:00:00:00 60 1176 1100 20.2 Apr-2024
    S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D SWOG 30MAY2023:00:00:00 13 30 510 3.3 Jun-2036
    S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT SWOG 01DEC2023:00:00:00 7 1 338 0.2 > 15 Yrs
MULT II S2101 Melan or HNSCC, Adv, Cabo + Nivo SWOG 14OCT2022:10:48:23 21 49 220 3.7 May-2028
OTHER I NRGGY022 Mult Site/Stg, Carboplat Clearance Predict NRG 18NOV2019:00:00:00   3   0.5  
  II A071701 BRAIN, Met, Geno-guided trial ALLIANCE 15AUG2019:00:00:00   2   0.0  
    A071702 BRAIN, Blockade Tx in Recurrent Glioblastoma ALLIANCE 30OCT2020:00:00:00   0   0.0  
    A092107 DDLPS. Palbocicli v Palbociclib+Cemiplimab ALLIANCE 24MAR2023:00:00:00   11   1.7  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   21   0.0  
    EA3191 HN, High Risk HNSCC, Adj +/- Pembro ECOG-ACRIN 08JAN2021:00:00:00   9   0.3  
    NRGHN010 HER2+ SGC, T-DM1 vs TH NRG 30SEP2022:00:00:00   4   0.3  
  II-III A092104 Uter,Adv, Olaparib+Temozolomide vs Inv Choice ALLIANCE 09DEC2022:00:00:00   6   0.5  
    EA3161 HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo ECOG-ACRIN 20JUN2019:00:00:00   69   1.8  
    NRGGY026 Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE NRG 12AUG2022:00:00:00   1   0.2  
    NRGHN005 HN, early stg P16-pos, randomize de-intensifi NRG 10JUL2019:00:00:00   8   0.0  
    NRGHN006 HN, Erly Stg, Biopsy vs Dissection NRG 08JUL2020:00:00:00   2   0.0  
    NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN NRG 27OCT2021:00:00:00   16   0.8  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   6   0.0  
  III AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo COG 30JUL2018:00:00:00   4     Temp Close
    ARST2031 RMS, Stg IV, VINO-AC+VINO-CPO vs VAC+VINO-CPO COG 13SEP2021:00:00:00   1   0.0  
    CCTGHN11 HN, All Stg, Guided Elec Contra Neck Tx CCTG 29SEP2022:00:00:00   1   0.2  
    CE7 Brain, 5+ Metastases, Radiosurg/Radiotherapy CCTG 25MAY2018:00:00:00   1   0.2  
    NRGBN003 Mening, Grd II, Observation vs Irradiation NRG 14JUN2017:00:00:00   3   0.0  
    NRGBN011 Brain, Lomustine + Temo vs Temo NRG 29NOV2021:00:00:00   4   0.0  
    NRGBN012 Brain, Pre- vs Post-Op Stereotactic Radiosurg NRG 31AUG2022:00:00:00   4   0.5  
    NRGGY019 Ovar, Stg II-IV, Pac/Carb/Let vs. Let Mono NRG 26AUG2019:00:00:00   2   0.2  
  OTHER A151804 irAEs, National Biorepository to Adv Studies ALLIANCE 31JAN2020:00:00:00   25   0.8  
PEOLC III S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol SWOG 15SEP2017:00:00:00   310 817   Feb-2024 Temp Close
PREV II EA2185 Panc, Impact of Panc Cyst Surveillance ECOG-ACRIN 16JAN2020:00:00:00   19   0.2  
    EA8184 Pros, Dbl Blind GTC vs Placebo ECOG-ACRIN 20MAY2021:00:00:00   6   0.3  
  III A211801 Breast, Preventive, Denosumab ALLIANCE 23FEB2022:00:00:00   1   0.2  
    EA1151 Prev, Tomosynthesis Mammographic Screening ECOG-ACRIN 06JUL2017:00:00:00   2485   11.3  
    NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs NRG 06OCT2021:00:00:00   11   1.7  
  OTHER A212102 Blind Ref Set for Multicancer Early Detection ALLIANCE 01AUG2022:00:00:00   121   8.8  
    NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO NRG 23JUN2020:00:00:00   10   0.3  
SURV III A211901 Cancer survivors who smoke, txt cessation ALLIANCE 01DEC2021:00:00:00   10   1.2  
SXQOL III A222004 Mult, Olanza vs Megestrol for Anorexia ALLIANCE 15OCT2021:00:00:00   6   0.5  
    ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis COG 14AUG2023:00:00:00   2   0.3  
    NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction NRG 19SEP2022:00:00:00   10   0.8  
    NRGCC011 Breast, Survivors, Cog Training NRG 02FEB2024:00:00:00   2   0.4  
    S2010 ASPEN: Brst, Stg I-III, ASM vs Pt Ed SWOG 17JAN2023:00:00:00 18 358 540 30.0 Jan-2025
    S2205 ICE COMPRESS: Reduction of CIPN from Taxanes SWOG 16MAR2023:00:00:00 16 181 777 18.2 Mar-2027
  OTHER S2013 I-CHECKIT: ICI toxicity risk prediction study SWOG 16AUG2021:00:00:00   2084 2062   May-2024 Temp Close
  PILOT EAQ202 Improving AYA PROs in EA Trials ECOG-ACRIN 28OCT2021:00:00:00   43   0.0  
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

19-JUL-2024 6:11

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase Comm. Int
grp
Stat
Center
Study NCIPROTO CA
Cntrl
Study
Temp
Close
OTHER CCD Y COG ACCL16N1 Guideline Consistent Treatment AYA ALL ACCL16N1CD Y Y
    Y ALLIANCE A231602C Blood Cancer, Assess Financial Difficulty A231602CD Y Y
    Y ALLIANCE A231901C Breast, Shared Decision Engagement System A231901CD Y  
  ERLYTX Y ECOG-ACRIN EAY191 ComboMATCH EAY191 N  
  LEUK Y SWOG MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials MYELOMATCH N  
  LUNG Y SWOG LUNGMAP NSCLC, Adv, Master LUNGMAP N  
    Y ALLIANCE A151216 ALCHEMIST0 - screening A151216 N  
  OTHER Y ALLIANCE A151804 irAEs, National Biorepository to Adv Studies A151804 N  
  PREV Y ALLIANCE A212102 Blind Ref Set for Multicancer Early Detection A212102 Y  
    Y NRG NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO NRG-CC008 Y  
  SXQOL Y SWOG S2013 I-CHECKIT: ICI toxicity risk prediction study S2013 Y Y
I OTHER Y NRG NRGGY022 Mult Site/Stg, Carboplat Clearance Predict NRG-GY022 N  
I-II LEUK Y SWOG S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 S1905 N  
    Y ECOG-ACRIN EA9152 ALL, T/B-Cell, Venetoclax + Vincristine EA9152 N  
  LYMPH Y ECOG-ACRIN E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin E4412 N  
II BREAST Y SWOG S2007 Breast, Brain Mets, Sacituzumab Govitecan S2007 N  
    Y NRG NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG-BR005 N Y
    Y ECOG-ACRIN EA1211 Breast, HER2+, NeoAdj Therapy EA1211 N  
  ERLYTX Y SWOG EAY191-S3 ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib EAY191-S3 N  
    Y ALLIANCE A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib A071401 N  
    Y ECOG-ACRIN EAY191E4 ComboMATCH-Pr. Tax-Tx Tumors, Pac+Nilotinib EAY191-E4 N  
    Y ALLIANCE EAY191A3 ComboMATCH-RAS-Mutant, All Stg, Palbo+Benim EAY191-A3 N  
  GI     EA2192 Panc, APOLLO   N  
    Y SWOG S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo S2001 N  
    Y SWOG S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect S1922 N  
    Y SWOG S2107 Colorectal, BRAF mut, Enc + CET +/-Nivo S2107 N  
    Y SWOG S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs S2104 N  
    Y ALLIANCE A022104 Rectal, Loc Adv, Triplet vs Doublet Chemo A022104 N  
    Y CCTG CCTGNE1 Midgut NET, Unresect, 177 Lut vs Ever CCTG-NE1 Y  
    Y ECOG-ACRIN EA2182 Anal, Erly, DECREASE EA2182 Y  
    Y ALLIANCE A022001 PANC, METS, Lu 177 Dotatate PRRT vs CAPTEM A022001 Y  
  GU Y SWOG S2200 pRCC, Adv, Cabo +/- Atezo S2200 N  
    Y SWOG S2210 Pros, High Risk, BRCA, Neoadj Carbo S2210 N  
    Y ECOG-ACRIN EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi EA8171 N  
    Y ALLIANCE A031701 Bladder, ddGC for MIBC with DDR Tumor Alt A031701 N  
    Y ALLIANCE A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) A031702 N  
    Y ALLIANCE A031803 Blad, NMIBC, Gemcitabine + MK-3475 A031803 N  
    Y NRG NRGGU011 Pros, Dbl Blinded RT +/- Androgen Dep Tx NRG-GU011 Y  
    Y NRG NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy NRG-GU012 N  
    Y ALLIANCE A021804 Adren, Advanced Stg, Temo w/wo Ola A021804 Y  
    Y ALLIANCE A031801 GU, mRCC, Cabozantinib +/- Radium-223 A031801 Y  
  LEUK     A042001 B-Cell ALL, Inotuzunab+chemo v Standard chemo   N  
        EA9213 T-ALL, dara-hyal for chemo refractory MRD   N  
    Y SWOG MM1YA-S01 AML, High Risk, Age <60, 7+3 vs experimental MM1YA-S01 N  
    Y ECOG-ACRIN EA9171 CML, Anti-PD-1 Pembrolizumab + TKIs EA9171 N  
    Y ALLIANCE A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat A041703 N  
  LUNG Y SWOG S1933 NSCLC, Stg II-III, RT + Atezo S1933 N  
    Y SWOG S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu S1900G N  
    Y SWOG S1900K MET Exon 14: Tepotinib +/- Ramucirumab S1900K N  
    Y SWOG S1900E KRAS G12C: Sotorasib (AMG 510) S1900E N  
    Y ECOG-ACRIN EA5162 NSCLS,StgIV/IIB,EGFR exon20 insertion,AZD9291 EA5162 N  
  LYMPH Y SWOG S2207 LBCL, Transplant Inelig, Targeted Tx + Tafa S2207 Y  
    Y SWOG S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation S2114 N  
    Y ALLIANCE A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P A051902 N  
  MELAN     A091903 Melan, Resected Mucosal, Adj Nivo +/- Cabo   N  
    Y ECOG-ACRIN EA6194 Melan, Stage IIIB-D, Pembro +/- CMP-001 EA6194 N  
    Y ECOG-ACRIN EA6192 Melan, Adv, Erly Discont of Antibdy Thrpy EA6192 N  
  MMYEL Y ECOG-ACRIN EAA173 MYEL, SMM, Rd +/- Daratumumab EAA173 Y  
  MULT Y SWOG S2101 Melan or HNSCC, Adv, Cabo + Nivo S2101 N  
  OTHER     A071702 BRAIN, Blockade Tx in Recurrent Glioblastoma   N  
    Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
    Y NRG NRGHN010 HER2+ SGC, T-DM1 vs TH NRG-HN010 N  
    Y ALLIANCE A071701 BRAIN, Met, Geno-guided trial A071701 N  
    Y ALLIANCE A092107 DDLPS. Palbocicli v Palbociclib+Cemiplimab A092107 N  
    Y ECOG-ACRIN EA3191 HN, High Risk HNSCC, Adj +/- Pembro EA3191 N  
  PREV     EA8184 Pros, Dbl Blind GTC vs Placebo   Y  
    Y ECOG-ACRIN EA2185 Panc, Impact of Panc Cyst Surveillance EA2185 Y  
PILOT SXQOL Y ECOG-ACRIN EAQ202 Improving AYA PROs in EA Trials EAQ202 Y  
II-III BREAST Y NRG NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG-BR002 N Y
  ERLYTX Y SWOG S2012 Small Cell NEC, Stg IV, Combo Chemo +/- Atezo S2012 N  
  GI     A022004 Colon, Stg II-III, Encor+Cetux vs SOC   Y  
    Y SWOG S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo S2303 Y  
    Y ECOG-ACRIN EA2197 Gal, Rando Perioperative TX EA2197 N  
    Y ECOG-ACRIN EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab EA2174 N  
    Y NRG NRGGI008 Colon, Stg III, Adj Chemo NRG-GI008 N  
  GU     A032103 Urothelial, All Stg, MRD-Based Adj Tx   Y  
    Y ECOG-ACRIN EA8192 Blad, High Grade UTUC, Durv + Chemo EA8192 N  
  LEUK Y ALLIANCE A041701 AML, Age 60+, Conv Chemo +/- Uproleselan A041701 N  
  LUNG Y ALLIANCE A082002 Lung, Adv, Systemic Tx +/- SBRT A082002 Y  
  LYMPH Y SWOG S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP S1918 Y  
  MELAN Y ECOG-ACRIN EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG NRGHN005 HN, early stg P16-pos, randomize de-intensifi NRG-HN005 Y  
    Y ECOG-ACRIN EA3161 HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo EA3161 N  
    Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y NRG NRGHN006 HN, Erly Stg, Biopsy vs Dissection NRG-HN006 Y  
    Y NRG NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN NRG-HN009 Y  
    Y ALLIANCE A092104 Uter,Adv, Olaparib+Temozolomide vs Inv Choice A092104 N  
    Y NRG NRGGY026 Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE NRG-GY026 Y  
III BREAST Y SWOG S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva S2206 Y  
    Y SWOG S2212 Breast, TNBC, Neoadj Chemo + Pembro S2212 Y  
    Y CCTG MA39 BREAST, Node-Pos, Reg RT vs No Reg RT CCTG MA.39 Y  
    Y ALLIANCE A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib A011801 Y  
    Y ALLIANCE A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab A012103 Y  
    Y NRG NRGBR009 Breast, EarlyStg, Adjuvant Chemo NRG-BR009 Y  
    Y NRG NRGBR007 Breast, Stg I, De-Escalation of Breast RT NRG-BR007 Y  
  CCD Y SWOG S1703 Met Breast, STM-monitoring v Usual Care S1703 Y  
    Y SWOG S2108CD Genomic Tumor Board vs Usual Practice S2108CD Y  
    Y SWOG S1912CD CREDIT, Fin Counseling to reduce Fin Hardship S1912CD Y  
    Y ALLIANCE A191901 Brst, Text/Motivational Intervention ET Adher A191901 Y  
  ERLYTX Y COG AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult AGCT1531 Y  
  GI Y NRG NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG-GI004 Y  
    Y NRG NRGGI006 Esophagus, Stg I-IVA, PBT vs IMRT NRG-GI006 Y  
    Y CCTG CCTGCO32 Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad CCTG-CO32 Y  
    Y ECOG-ACRIN EA2222 Colorectal, Stg II-III, Hep Art Infusion EA2222 N  
    Y ALLIANCE A021806 Pancreas, Perioperative vs Adjuvant Chemo A021806 Y  
    Y ALLIANCE A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo A022102 N  
    Y ECOG-ACRIN EA2176 Anal, Met, Immune Check Pt Inhibition + Chemo EA2176 N  
  GU Y SWOG S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum S1802 Y  
    Y SWOG S1937 Blad, Mets, Eribulin + Gem vs SOC S1937 N  
    Y SWOG S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only S1931 N  
    Y ECOG-ACRIN EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT EA8134 Y  
    Y NRG NRGGU013 Prostate, High-Risk, Five Fraction Radiation NRG-GU013 Y  
    Y NRG NRGGU010 Pros, Parallel De-Intens & Intens Trials NRG-GU010 Y  
    Y ECOG-ACRIN EA8191 Pros, Local vs Systemic Thrpy EA8191 Y  
    Y ECOG-ACRIN EA8212 Blad, NMIBC, BRIDGE EA8212 Y  
    Y NRG NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide NRG-GU008 Y  
    Y NRG NRGGU009 Pros, PREDICT-RT NRG-GU009 Y  
  LEUK Y SWOG S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O S1925 Y  
    Y ALLIANCE A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo A041501 N  
    Y ECOG-ACRIN EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab EA9181 N  
  LUNG Y SWOG S1827 SCLC, MRI Surveillance +/- PCI S1827 Y  
    Y SWOG S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo S1914 Y  
    Y SWOG S2302 NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC S2302 N  
    Y NRG NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo NRG-LU008 Y  
    Y ALLIANCE A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO A081801 Y  
    Y ECOG-ACRIN EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 EA5182 N  
  LYMPH Y ECOG-ACRIN EA4151 Lymph, AHCT +/-Ritux, MRD Neg EA4151 N  
    Y ALLIANCE A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub A052101 Y  
    Y COG ANHL1931 PMBCL, Chemo-Immunotherapy +/- Nivo ANHL1931 N  
    Y COG AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy AHOD2131 Y  
  MELAN Y MASC S2015 MELAN, Stg I-II, 1cm v 2cm excision margins S2015 N  
  MMYEL Y SWOG S1803 MM, Maintenance, Len vs Len/Dara S1803 Y  
    Y SWOG S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D S2209 Y  
    Y SWOG S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT S2213 Y  
    Y ECOG-ACRIN EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) EAA181 Y  
  OTHER     CE7 Brain, 5+ Metastases, Radiosurg/Radiotherapy   Y  
    Y NRG NRGBN003 Mening, Grd II, Observation vs Irradiation NRG-BN003 Y  
    Y COG AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo AGCT1532 Y Y
    Y COG ARST2031 RMS, Stg IV, VINO-AC+VINO-CPO vs VAC+VINO-CPO ARST2031 N  
    Y CCTG CCTGHN11 HN, All Stg, Guided Elec Contra Neck Tx CCTG-HN11 Y  
    Y NRG NRGBN011 Brain, Lomustine + Temo vs Temo NRG-BN011 Y  
    Y NRG NRGBN012 Brain, Pre- vs Post-Op Stereotactic Radiosurg NRG-BN012 Y  
    Y NRG NRGGY019 Ovar, Stg II-IV, Pac/Carb/Let vs. Let Mono NRG-GY019 N  
  PEOLC Y SWOG S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol S1501 Y Y
  PREV     A211801 Breast, Preventive, Denosumab   Y  
    Y ECOG-ACRIN EA1151 Prev, Tomosynthesis Mammographic Screening EA1151 N  
    Y NRG NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs NRG-CC005 Y  
  SURV Y ALLIANCE A211901 Cancer survivors who smoke, txt cessation A211901 Y  
  SXQOL     NRGCC011 Breast, Survivors, Cog Training   Y  
    Y SWOG S2010 ASPEN: Brst, Stg I-III, ASM vs Pt Ed S2010 Y  
    Y SWOG S2205 ICE COMPRESS: Reduction of CIPN from Taxanes S2205 Y  
    Y COG ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis ACCL1931 Y  
    Y ALLIANCE A222004 Mult, Olanza vs Megestrol for Anorexia A222004 Y  
    Y NRG NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction NRG-CC010 Y  
        A022101      
    Y ALLIANCE EAY191A6 EAY191-A6    

19-JUL-2024 6:11

PHASE III SWOG COORDINATED OPEN STUDIES

SORTED BY STUDY ID

Protocol
Number
Study Accrual
Goal
Open
Stat/Date
Months
Open
Accrual
as of
01Jan02
Current Accrual Proj.
Annual
Accr.
Rate
EXPCLOSE Proj.
Study
Duration
(Years)
S1501 S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol (PEOLC) 817 T-09/15/17 82 310 310 2 > 15 Yrs > 15 Yrs
S1703 S1703 Met Breast, STM-monitoring v Usual Care (CCD) 739 Y-07/16/18 72 346 346 66 Jun-2030 11.9
S1802 S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum (GU) 1273 Y-09/17/18 70 823 823 130 Dec-2027 9.3
S1803 S1803 MM, Maintenance, Len vs Len/Dara (MMYEL) 1100 Y-06/27/19 60 1176 1176 242 Apr-2024 4.8
S1827 S1827 SCLC, MRI Surveillance +/- PCI (LUNG) 668 Y-01/10/20 54 230 230 84 Sep-2029 9.7
S1912CD S1912CD CREDIT, Fin Counseling to reduce Fin Hardship (CCD) 326 Y-07/26/21 35 267 267 186 Oct-2024 3.2
S1914 S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo (LUNG) 480 Y-03/25/20 51 397 397 182 Dec-2024 4.7
S1918 S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP (LYMPH) 422 Y-03/19/21 40 110 110 48 Dec-2030 9.8
S1925 S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O (LEUK) 247 Y-12/14/20 43 109 109 42 Oct-2027 6.8
S1931 S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only (GU) 332 Y-11/16/20 44 98 98 24 Mar-2034 13.3
S1937 S1937 Blad, Mets, Eribulin + Gem vs SOC (GU) 184 Y-02/16/21 41 39 39 32 Jan-2029 7.9
S2010 S2010 ASPEN: Brst, Stg I-III, ASM vs Pt Ed (SXQOL) 540 Y-01/17/23 18 358 358 360 Jan-2025 2.0
S2012 S2012 Small Cell NEC, Stg IV, Combo Chemo +/- Atezo (ERLYTX) 189 Y-12/02/21 31 52 52 36 Apr-2028 6.4
S2108CD S2108CD Genomic Tumor Board vs Usual Practice (CCD) 1182 Y-08/22/22 22 1098 1098 588 Aug-2024 2.0
S2205 S2205 ICE COMPRESS: Reduction of CIPN from Taxanes (SXQOL) 777 Y-03/16/23 16 181 181 218 Mar-2027 4.0
S2206 S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva (BREAST) 960 Y-10/30/23 8 30 30 60 > 15 Yrs > 15 Yrs
S2209 S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D (MMYEL) 510 Y-05/30/23 13 30 30 40 Jun-2036 13.1
S2212 S2212 Breast, TNBC, Neoadj Chemo + Pembro (BREAST) 2400 Y-07/21/23 11 213 213 348 Oct-2030 7.2
S2213 S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT (MMYEL) 338 Y-12/01/23 7 1 1 2 > 15 Yrs > 15 Yrs
S2302 S2302 NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC (LUNG) 700 Y-03/06/23 16 554 554 522 Oct-2024 1.6
S2303 S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo (GI) 224 Y-05/06/24 2 1 1      
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.